GeoVax Labs, Inc. is the subject of an amended Schedule 13G filing by Jane Street Group, LLC and its subsidiaries Jane Street Capital, LLC and Jane Street Global Trading, LLC. The group reports beneficial ownership of 315,275 shares of GeoVax common stock, representing 4.3% of the class as of June 30, 2026. All reported GeoVax shares are held with shared voting and dispositive power; none are held with sole voting or dispositive authority. Subsidiaries Jane Street Capital, LLC and Jane Street Global Trading, LLC report shared voting and dispositive power over 161,270 and 154,005 shares, respectively. The filing indicates ownership of 5 percent or less of GeoVax’s outstanding common stock.
GeoVax Labs, Inc. reported Q2 2026 results with no revenue and a continued net loss as it advances its mpox/smallpox and oncology programs. For the three months ended June 30, 2026, net loss was $4.43 million, improving from $5.37 million a year earlier, as operating expenses declined to $4.44 million from $6.27 million driven by lower research and development spending.
For the first half of 2026, GeoVax recorded a net loss of $9.69 million versus $10.73 million in the prior-year period. Cash and cash equivalents were $3.14 million at June 30, 2026, with working capital of $1.46 million. The company raised approximately $7.25 million in the first half through common stock and warrant transactions, increasing shares outstanding to 7,369,243 from 1,732,147 at year-end 2025.
Management states existing cash is expected to fund operations only into September 2026 and discloses substantial doubt about the ability to continue as a going concern absent additional capital. Strategy has been reprioritized around the GEO-MVA mpox/smallpox vaccine and Gedeptin® oncology program, with the GEO-CM04S1 COVID-19 vaccine candidate discontinued. GeoVax also highlights new Nasdaq rules requiring a $5 million market value of listed securities, noting its common stock trades near that threshold and could face delisting risk.
GeoVax Labs, Inc. reported results for the quarter and six months ended June 30, 2026 and outlined progress on its lead programs. The company is preparing a pivotal GEO-MVA immunobridging study under an expedited regulatory pathway supported by Scientific Advice from the European Medicines Agency, with initiation planned in the second half of 2026. GeoVax is also advancing its Gedeptin gene-directed enzyme prodrug therapy in combination immunotherapy strategies and holds an exclusive intellectual property license from Emory University covering Gedeptin with immune checkpoint inhibitors.
For the three months ended June 30, 2026, GeoVax reported a net loss of $4,426,578, or $0.97 per share, versus $5,369,783, or $8.74 per share, a year earlier. For the six months, net loss was $9,688,499, or $2.94 per share, compared with $10,727,434, or $19.72 per share, in 2025. No revenue was recognized in 2026 following termination of the BARDA COVID-19 vaccine contract in 2025, versus $852,282 and $2,489,145 of government contract revenue in the prior-year quarter and six-month period. Research and development expenses were $3,110,508 for the quarter and $7,013,971 year-to-date, down from $4,728,998 and $10,083,586, mainly due to reduced GEO-CM04S1 COVID-19 vaccine activities after a May 2026 portfolio reprioritization. General and administrative expenses were $1,331,564 for the quarter and $2,700,982 for six months, compared with $1,542,190 and $3,229,635, reflecting lower investor relations and stock-based compensation costs.
As of June 30, 2026, GeoVax reported cash and cash equivalents of $3,143,000, similar to $3,086,000 at December 31, 2025. Total assets were $4,643,000, with total liabilities of $2,882,000 and stockholders’ equity of $1,761,000. Common shares outstanding increased to 7,369,243 from 1,732,147 at year-end. The company’s strategic focus now centers on GEO-MVA for mpox and smallpox and Gedeptin for solid tumors, following the decision to discontinue active development of the GEO-CM04S1 COVID-19 vaccine candidate.
GeoVax Labs, Inc. received a notice from Nasdaq on July 7, 2026 that it is not in compliance with the $2,500,000 minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), and it also does not meet the alternative market value or net income standards. The company has 45 calendar days, until August 21, 2026, to submit a compliance plan, after which Nasdaq Staff may grant up to a 180-day extension. Trading of the company’s common stock under the symbol GOVX on the Nasdaq Capital Market continues for now, while GeoVax evaluates options and prepares a plan; there is a risk of eventual delisting if compliance is not regained.
GeoVax Labs, Inc. director John N. Spencer Jr reported receiving a grant of stock options covering 6,000 shares of GeoVax common stock. The options have an exercise price of $1.18 per share, become exercisable on June 17, 2027, and expire on June 17, 2036. Following this grant, he holds 6,000 stock options directly.
GeoVax Labs, Inc. director Morgan Jayne received a grant of stock options covering 6,000 shares of common stock. The options have an exercise price of $1.18 per share, become exercisable on June 17, 2027, and are scheduled to expire on June 17, 2036. This is a compensation-related award reported as an acquisition of derivative securities, not an open-market purchase or sale of common stock.
GeoVax Labs, Inc. director Robert T. McNally received a grant of stock options covering 6,000 shares of common stock. The options have a $1.18 per-share exercise price, become exercisable on June 17, 2027, and expire on June 17, 2036. Following this compensation-related award, his directly held derivative position from this grant totals 6,000 options, and the filing shows no open-market buying or selling activity.
GeoVax Labs director Nicole Lemerond received a grant of 6,000 stock options for GeoVax Labs, Inc. common stock. These options were awarded at an exercise price of $1.18 per share and are scheduled to expire on June 17, 2036. Following this grant, she holds 6,000 derivative securities directly, reflecting a routine equity compensation award rather than an open-market purchase or sale.
GeoVax Labs director Dean G. Kollintzas received a grant of 6,000 stock options on common stock. The options have a conversion or exercise price of $1.18 per share and relate to 6,000 underlying common shares. They expire on June 17, 2036, and his derivative holdings after this award total 6,000 options held directly.
GeoVax Labs, Inc. director Randal D. Chase received a grant of stock options covering 6,000 shares of common stock. The options carry an exercise price of $1.18 per share, become exercisable on June 17, 2027, and expire on June 17, 2036. Following this award, he holds 6,000 options directly.